Diabetic Macular Edema (DME) Completed Phase 2 Trials for Dexamethasone (DB01234)

Also known as: Diabetic Macular Edema(DME) / Diabetic Macular Oedema / Macular Edema, Diabetic / Diabetic Macular Edema / Diabetic retinal oedema / Diabetic retinal edema

IndicationStatusPhase
DBCOND0060562 (Diabetic Macular Edema (DME))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01787669Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular OedemaTreatment
NCT03608839Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical TrialTreatment
NCT00464685Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular EdemaTreatment
NCT00799227Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular EdemaTreatment
NCT01284478Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract SurgeryTreatment
NCT01571232Ozurdex for Treatment of Recalcitrant Diabetic Macular EdemaTreatment
NCT01945866Phase II Combination Steroid and Anti-VEGF for Persistent DMETreatment
NCT01951066Diabetic Macular Edema Treated With Ozurdex (DMEO)